HHS Public Access

Author manuscript

J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 September 01.

Published in final edited form as:

J Acquir Immune Defic Syndr. 2017 September 01; 76(1): e21–e22. doi:10.1097/QAI.0000000000001457.

Authors' Response

David Alain Wohl, MD,
The University of North Carolina

Carol E. Golin, MD,
The University of North Carolina

Sonia Napravnik, PhD,
The University of North Carolina

Kevin Knight, PhD, and
Texas Christian University

Patrick M. Flynn, PhD
Texas Christian University

In their letter, Drobeniuc and Spaulding question the selected analytic approach to our randomized, controlled trial of a comprehensive intervention to maintain plasma HIV RNA suppression following prison release. Specifically, issue is taken with the use of an intent-to-treat analysis comparing the rates of virologic suppression at 24 weeks following prison release between the two study arms. While investigators use a variety of approaches to address missing outcome data in intent-to-treat analyses, including complete case analyses and simple imputation methods, we recognized that in this trial of men and women re-entering their communities following incarceration, missing data due to lost to follow-up and re-incarceration would not be trivial. To address this, the primary analysis employed multiple imputation to estimate missing outcomes based on ten major characteristics measured at baseline.^{1, 2} Therefore, all participants contributed data to the primary endpoint of this study, regardless of whether or not the participant was re-incarcerated.

The multiple imputation modeling, in our view, is preferable to the actual measurement of viral load of those re-incarcerated for a number of reasons. Foremost, the overarching aim of our trial was to test an intervention to maintain viral suppression in the community following incarceration in order to reduce the risk of secondary transmission of the virus. Those who are re-incarcerated are no longer in these communities and, therefore, the determination of the efficacy of the intervention to reduce secondary transmission is no longer possible. Our model estimates the rates of viral suppression had these men and women remained in their communities. Additionally, the study intervention was designed to encourage and support community HIV care and treatment adherence, and not viral suppression while in a

Corresponding Author/Address for Reprints: David Alain Wohl, MD – The University of North Carolina, 130 Mason Farm Road, Campus Box 7215, Chapel Hill, NC 27599, (919) 843-2723, wohl@med.unc.edu.

Conflicts of Interest: None for any authors

correctional facility. The systems in place to administer and support HIV therapy in prisons and jails are starkly different than those found in the community.

Importantly, there is no reason to believe that the inclusion of viral load data from the participants who were re-incarcerated would have altered the main findings of our trial. That the study intervention would have led to better or worse odds of viral suppression during re-incarceration is highly unlikely, and other interventions should be developed and tested to improve HIV outcomes during incarceration.

We do agree with Drobeniuc and Spaulding that there are consequences of mass incarceration, especially among HIV-infected persons, that impede success after prison release. The absence of a significant difference between the study arms in the primary and almost all secondary outcomes, suggests to us that there are strong societal forces that our intervention did not address. That a substantial proportion of HIV-infected people in the US, particularly those living in deep poverty, can only achieve and maintain desirable health outcomes while incarcerated implicates these forces as the main target for change, rather than the behaviors of those they affect.

Acknowledgments

Sources of Funding: This research was supported by funding from the National Institute of Drug Abuse (NIDA) at the National Institutes of Health (NIH) (R01-DA030793: MPI Wohl, Golin, Flynn, Knight) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K24-DA037101 PI:Wohl; K24-HD06920 PI: Golin). Additional support was provided by the University of North Carolina Center for AIDS Research (CFAR) (P30 AI-50410).

References

1. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. *New Engl J Med*. 2012; 367:1355–1360. [PubMed: 23034025]
2. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ*. 2009; 338:b2393. [PubMed: 19564179]